(Q37449905)

20 August 2017

1 reference

title

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment (English)

1 reference

20 August 2017

1 reference

1 reference

1 reference

2

Anthony H V Schapira

1 reference

20 August 2017

1

K Ray Chaudhuri

1 reference

20 August 2017

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

8

1 reference

20 August 2017

464-474

1 reference

20 August 2017

5

1 reference

Non-motor symptoms of Parkinson's disease: diagnosis and management

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Factors impacting on quality of life in Parkinson's disease: results from an international survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Direct economic impact of Parkinson's disease: A research survey in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Resource use and costs in a Swedish cohort of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Quantitation of non-motor symptoms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Non-dopaminergic treatments in development for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Early Parkinson's disease and non-motor issues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Range of neuropsychiatric disturbances in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Anxiety and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Apathy: a treatable syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Motivation, reward, and Parkinson's disease: influence of dopatherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Cognitive deficits in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Visual dysfunction in Parkinson disease without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

What causes mental dysfunction in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Dopaminergic modulation of cortical function in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Dopamine: Stimulation-Induced Release from Central Neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

The sleep switch: hypothalamic control of sleep and wakefulness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Sleep disorders in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Restless legs syndrome: an update on treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Restless legs syndrome and PD: a review of the evidence for a possible association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Exploring the relationship between Parkinson disease and restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Akathisia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

The effects of pramipexole in REM sleep behavior disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Role of subcutaneous apomorphine in parkinsonian voiding dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effects of dopaminergic treatment on bladder function in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effect of subthalamic deep brain stimulation on the function of the urinary bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Sexual Dysfunction in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Penile erection evoked from forebrain structures in Macaca mulatta.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Deep brain stimulation of the thalamus can influence penile erection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Clinical risk-benefit assessment of dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Apomorphine-induced penile erections in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Defecatory function in Parkinson's disease: response to apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

The role of the basal ganglia in nociception and pain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Neurophysiological, pharmacological and behavioral evidence for medial thalamic mediation of cocaine-induced dopaminergic analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Pain as a Nonmotor Symptom of Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Painful Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Neurophysiologic study of central pain in patients with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Quantitative measurement of pain sensation in patients with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Distorted color discrimination in 'de novo' parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

A model of the Parkinsonian visual system: support for the dark adaptation hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

[Non-motor fluctuations in Parkinson's disease]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Nonmotor fluctuations in Parkinson's disease: frequent and disabling

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970068-7

7 January 2021

10.1016/S1474-4422(09)70068-7

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19375664